The Kampo Medicine Yokukansan Decreases MicroRNA-18 Expression and Recovers Glucocorticoid Receptors Protein Expression in the Hypothalamus of Stressed Mice

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Shimizu, Shoko ^a   Tanaka, Takashi ^a   Takeda, Takashi ^a   Tohyama, Masaya ^a,b   Miyata, Shingo ^a  

^a KINKI UNIVERSITY   (Japan)

^b OSAKA GENERAL MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTERONE; GLUCOCORTICOID RECEPTOR; KAMPO; MICRORNA; MICRORNA 124; MICRORNA 124A; MICRORNA 18; UNCLASSIFIED DRUG; YOKUKANSAN; GLUCOCORTICOID; HERBACEOUS AGENT; MIRN18 MICRORNA, MOUSE; YI-GAN SAN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHINESE MEDICINE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DOWN REGULATION; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RANDOMIZATION; ADVERSE EFFECTS; ANIMAL; BIOSYNTHESIS; BLOOD; DRUG EFFECTS; DRUG THERAPY; GENE EXPRESSION REGULATION; GENETICS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MENTAL STRESS; METABOLISM; PATHOPHYSIOLOGY;

MUS;

ANIMALS; CORTICOSTERONE; DRUGS, CHINESE HERBAL; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; HYPOTHALAMUS; MEDICINE, KAMPO; MICE; MICRORNAS; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PITUITARY-ADRENAL SYSTEM; STRESS, PSYCHOLOGICAL;

EID: 84935902617     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/797280     Document Type: Article

References (48)

1. V. Bartanusz, D. Jezova, L. T. Bertini, F. J. H. Tilders, J.-M. Aubry, and J. Z. Kiss, "Stress-induced increase in vasopressin and corticotropin-releasing factor expression in hypophysiotrophic paraventricular neurons, " Endocrinology, vol. 132, no. 2, pp. 895-902, 1993.
2. K. S. Kendler, L. M. Karkowski, and C. A. Prescott, "Causal relationship between stressful life events and the onset of major depression, " American Journal of Psychiatry, vol. 156, no. 6, pp. 837-841, 1999.
3. G. Aguilera and C. Rabadan-Diehl, "Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation, " Regulatory Peptides, vol. 96, no. 1-2, pp. 23-29, 2000.
4. P. W. Gold and D. S. Charney, "Diseases of the mind and brain: depression: a disease of the mind, brain, and body., " American Journal of Psychiatry, vol. 159, no. 11, p. 1826, 2002.
5. B. S. McEwen, "Protection and damage from acute and chronic stress: allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders, " Annals of the New York Academy of Sciences, vol. 1032, pp. 1-7, 2004.
6. J. P. Herman, P. D. Patel, H. Akil, and S. J. Watson, "Localization and regulation of glucocorticoid and mineralocorticoid receptor messenger RNAs in the hippocampal formation of the rat, " Molecular Endocrinology, vol. 3, no. 11, pp. 1886-1894, 1989.
7. D. Zhe, H. Fang, and S. Yuxiu, "Expressions of hippocampal mineralocorticoid receptor (MR) and glucocorticoid receptor (GR) in the single-prolonged stress-rats, " Acta Histochemica et Cytochemica, vol. 41, no. 4, pp. 89-95, 2008.
8. F. Thomson and M. Craighead, "Innovative approaches for the treatment of depression: targeting theHPAaxis, " Neurochemical Research, vol. 33, no. 4, pp. 691-707, 2008.
9. C. M. Pariante and S. L. Lightman, "The HPA axis in major depression: classical theories and new developments, " Trends in Neurosciences, vol. 31, no. 9, pp. 464-468, 2008.
10. E. R. De Kloet, M. Joels, and F. Holsboer, "Stress and the brain: from adaptation to disease, " Nature Reviews Neuroscience, vol. 6, no. 6, pp. 463-475, 2005.
11. M. P. Boyle, J. A. Brewer, M. Funatsu, et al., "Acquired deficit of forebrain glucocorticoid receptor produces depression-like changes in adrenal axis regulation and behavior, " Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 2, pp. 473-478, 2005.
12. E. R. De Kloet and J. M. H. M. Reul, "Feedback action and tonic influence of corticosteroids on brain function: a concept arising from the heterogeneity of brain receptor systems, " Psychoneuroendocrinology, vol. 12, no. 2, pp. 83-105, 1987.
13. J. M. H. M. Reul and E. R. De Kloet, "Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation, " Endocrinology, vol. 117, no. 6, pp. 2505-2511, 1985.
14. B. Myers, J. M. McKlveen, and J. P. Herman, "Glucocorticoid actions on synapses, circuits, and behavior: implications for the energetics of stress, " Frontiers inNeuroendocrinology, vol. 35, no. 2, pp. 180-196, 2014.
15. T. Hiratsuka, S. Matsuzaki, S. Miyata, et al., "Yokukansaninhibits neuronal death during ER stress by regulating the unfolded protein response, " PLoS ONE, vol. 5, no. 10, Article ID e13280, 2010.
16. R. W. Carthew, "Gene regulation by microRNAs, " Current Opinion in Genetics & Development, vol. 16, no. 2, pp. 203-208, 2006.
17. Y. Wang, H. M. Stricker, D. Gou, and L. Liu, "MicroRNA: past and present, " Frontiers in Bioscience, vol. 12, no. 6, pp. 2316-2329, 2007.
18. X. Cao, G. Yeo, A. R. Muotri, T. Kuwabara, and F. H. Gage, "Noncoding RNAs in the mammalian central nervous system, " Annual Review of Neuroscience, vol. 29, pp. 77-103, 2006.
19. T. Dalmay, "MicroRNAs and cancer, " Journal of Internal Medicine, vol. 263, no. 4, pp. 366-375, 2008.
20. G. Stefani and F. J. Slack, "Small non-coding RNAs in animal development, " Nature ReviewsMolecular Cell Biology, vol. 9, no. 3, pp. 219-230, 2008.
21. H. Chiu, A. Alqadah, and C. Chang, "The role of microRNAs in regulating neuronal connectivity, " Frontiers in Cellular Neuroscience, vol. 7, article 283, 2014.
22. E. Vreugdenhil, C. S. L. Verissimo, R. Mariman, et al., "MicroRNA 18 and 124a down-regulate the glucocorticoid receptor: implications for glucocorticoid responsiveness in the brain, " Endocrinology, vol. 150, no. 5, pp. 2220-2228, 2009.
23. S. Miyata, Y. Koyama, K. Takemoto, et al., "Plasma corticosterone activates SGK1 and induces morphological changes in oligodendrocytes in corpus callosum, " PLoS ONE, vol. 6, no. 5, Article ID e19859, 2011.
24. H. Kanno, Z. Kawakami, K. Mizoguchi, Y. Ikarashi, Y. Kase, and H. Ariga, "Yokukansan, a kampo medicine, protects PC12 cells from glutamate-induced death by augmenting gene expression of cystine/glutamate antiporter system XC, " PLoS ONE, vol. 9, no. 12, Article ID e116275, 2014.
25. T. Ishikawa, S. Miyata, Y. Koyama, et al., "Transient expression of Xpn, an XLMR protein related to neurite extension, during brain development and participation in neurite outgrowth, " Neuroscience, vol. 214, pp. 181-191, 2012.
26. M. N. Silverman and E. M. Sternberg, "Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction, " Annals of the New York Academy of Sciences, vol. 1261, no. 1, pp. 55-63, 2012.
27. S. Imamura, M. Tabuchi, H. Kushida, et al., "The bloodbrain barrier permeability of geissoschizine methyl ether in Uncaria hook, a galenical constituent of the traditional Japanese medicine yokukansan, " Cellular and Molecular Neurobiology, vol. 31, no. 5, pp. 787-793, 2011.
28. A. Nishi, T. Yamaguchi, K. Sekiguchi, et al., "Geissoschizine methyl ether, an alkaloid in Uncaria hook, is a potent serotonin1A receptor agonist and Candidate for amelioration of aggressiveness and sociality by yokukansan, " Neuroscience, vol. 207, pp. 124-136, 2012.
29. M. Tabuchi, S. Imamura, Z. Kawakami, Y. Ikarashi, and Y. Kase, "The blood-brain barrier permeability of 18β-glycyrrhetinic acid, a major metabolite of glycyrrhizin in Glycyrrhiza root, a constituent of the traditional Japanese medicine yokukansan, " Cellular and Molecular Neurobiology, vol. 32, no. 7, pp. 1139-1146, 2012.
30. H. Kushida, M. Fukutake, M. Tabuchi, et al., "Simultaneous quantitative analyses of indole and oxindole alkaloids of Uncaria Hook in rat plasma and brain after oral administration of the traditional Japanese medicine Yokukansan using highperformance liquid chromatography with tand em mass spectrometry, " Biomedical Chromatography, vol. 27, no. 12, pp. 1647-1656, 2013.
31. Z. Liposits, R. M. Uht, R. W. Harrison, F. P. Gibbs, W. K. Paull, and M. C. Bohn, "Ultrastructural localization of glucocorticoid receptor (GR) in hypothalamic paraventricular neurons synthesizing corticotropin releasing factor (CRF), "Histochemistry, vol. 87, no. 5, pp. 407-412, 1987.
32. N. Laflamme, N. Barden, and S. Rivest, "Corticotropin-releasing factor and glucocorticoid receptor (GR) gene expression in the paraventricular nucleus of immune-challenged transgenic mice expressing type II GR antisense ribonucleic acid, " Journal of Molecular Neuroscience, vol. 8, no. 3, pp. 165-179, 1997.
33. Y. Matsuda, T. Kishi, H. Shibayama, and N. Iwata, "Yokukansan in the treatment of behavioral and psychological symptoms of dementia: a systematic review and meta-analysis of rand omized controlled trials, "Human Psychopharmacology, vol. 28, no. 1, pp. 80-86, 2013.
34. K. Matsumoto, Q. Zhao, Y. Niu, et al., "Kampo formulations, chotosan, and yokukansan, for dementia therapy: existing clinical and preclinical evidence, " Journal of Pharmacological Sciences, vol. 122, no. 4, pp. 257-269, 2013.
35. R. Kumar and E. B. Thompson, "Transactivation functions of the N-terminal domains of nuclear hormone receptors: protein folding and coactivator interactions, " Molecular Endocrinology, vol. 17, no. 1, pp. 1-10, 2003.
36. R. H. DeRijk, M. J. Schaaf, F. J. Stamet al., "Very low levels of the glucocorticoid receptor β isoform in the human hippocampus as shown by Taqman RT-PCR and immunocytochemistry, " Molecular Brain Research, vol. 116, no. 1-2, pp. 17-26, 2003.
37. M. J. M. Schaaf and J. A. Cidlowski, "Molecular mechanisms of glucocorticoid action and resistance, " Journal of Steroid Biochemistry and Molecular Biology, vol. 83, no. 1-5, pp. 37-48, 2002.
38. R. H. Derijk, M. J. M. Schaaf, G. Turner, et al., "A human glucocorticoid receptor gene variant that increases the stability of the glucocorticoid receptor β-isoform mRNA is associated with rheumatoid arthritis, " Journal of Rheumatology, vol. 28, no. 11, pp. 2383-2388, 2001.
39. N. Z. Lu and J. A. Cidlowski, "Glucocorticoid receptor isoforms generate transcription specificity, " Trends in Cell Biology, vol. 16, no. 6, pp. 301-307, 2006.
40. S. Uchida, A. Nishida, K. Hara, et al., "Characterization of the vulnerability to repeated stress in Fischer 344 rats: possible involvement of microRNA-mediated down-regulation of the glucocorticoid receptor, " European Journal of Neuroscience, vol. 27, no. 9, pp. 2250-2261, 2008.
41. R. V. Durairaj and E. R. Koilmani, "Environmental enrichment modulates glucocorticoid receptor expression and reduces anxiety in Indian field male mouse Mus booduga through up-regulation of microRNA-124a, " General and Comparative Endocrinology, vol. 199, pp. 26-32, 2014.
42. A. J. Dunn, "Cytokine activation of the HPA axis, " Annals of the New York Academy of Sciences, vol. 917, pp. 608-617, 2000.
43. M. Hamon and P. Blier, "Monoamine neurocircuitry in depression and strategies for new treatments, " Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 45, pp. 54-63, 2013.
44. K. Terawaki, Y. Ikarashi, K. Sekiguchi, Y. Nakai, and Y. Kase, "Partial agonistic effect of yokukansan on human recombinant serotonin 1A receptors expressed in the membranes of Chinese hamster ovary cells, " Journal of Ethnopharmacology, vol. 127, no. 2, pp. 306-312, 2010.
45. N. Egashira, K. Iwasaki, A. Ishibashi, et al., "Repeated administration of Yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT)2β receptors in the prefrontal cortex, " Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 32, no. 6, pp. 1516-1520, 2008.
46. H. Kanno, K. Sekiguchi, T. Yamaguchi, et al., "Effect of yokukansan, a traditional Japanese medicine, on social and aggressive behaviour of para-chloroamphetamine-injected rats, " Journal of Pharmacy and Pharmacology, vol. 61, no. 9, pp. 1249-1256, 2009.
47. T. Ueda, S. Ugawa, Y. Ishida, and S. Shimada, "Geissoschizine methyl ether has third-generation antipsychotic-like actions at the dopamine and serotonin receptors, " European Journal of Pharmacology, vol. 671, no. 1-3, pp. 79-86, 2011.
48. N. P. Maric and M. Adzic, "Pharmacological modulation of HPA axis in depression-new avenues for potential therapeutic benefits, " PsychiatriaDanubina, vol. 25, no. 3, pp. 299-305, 2013.